Viral Genetics Creates Subsidiary to Develop Cancer Therapy
... in animal studies to not only directly cause cancer cells to die but also to synergize with existing ... disruption is a concept that has tantalized cancer researchers for decades. We believe that we ... the senior director for infectious disease and cancer at Hollis Eden Pharmaceuticals. He served as ...Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
... on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a ... we believe may offer future benefit to cancer patients," said Dan Passeri, Curis President and ... basal cell carcinoma, metastatic colorectal cancer and advanced ovarian cancer," said Michael Gray, ...The Breast Cancer Therapeutics Market in Australia
... /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the ...TSH Testing Raises Awareness of Importance of Thyroid Health
... in the U.S. even though the rate of thyroid cancer has nearly tripled since 1980," said Joseph ... four counties neighboring Indian Point, thyroid cancer is 70% above the U.S. rate and newborn ... a damaged thyroid can be." "The National cancer Institute is looking at Iodine 131, the most ...ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
... Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research ... and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer ... novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its ...Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
... Product revenue from the Onco type DX(R) breast cancer test was $35.2 million in the second quarter of ... type DX access and coverage to a broader breast cancer population," said Kim Popovits, President and ... Onco type DX to more than 100,000 breast cancer patients and today remain on track to make our ...Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
... "Her leadership and knowledge of all aspects of cancer drug development will be very important as we ... at an exciting target at the forefront of current cancer drug research." Dr. Hausman joins Oncothyreon ... potential to improve the lives and outcomes of cancer patients. For more information, visit ...W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry
... /PRNewswire/ -- Anyone touched by the ravages of cancer knows the rapidly growing, opportunistic cells don't play fair. But in order to expose exactly how cancer cells cheat their host, scientists must first ... - which enhances the potential for learning how cancer cells cheat - Fred ...Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
... of Lung Cancer's 13th World Conference on Lung cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital cancer Centre, Ottawa, Ontario, involved 16 patients who ... patients with stage IIIb/IV non-small cell lung cancer (NSCLC). As of the time of data analysis in ...CuraGen Reports Second Quarter 2009 Financial Results
... the development opportunities for CR011 in breast cancer and melanoma," commented Dr. Timothy M. Shannon, ... forward to presenting updated data for the breast cancer study in the second half of 2009." In ... development opportunities for CR011 in breast cancer and melanoma and the expected timing for ...Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
... developer of oncology compounds directed to cancer stem cell targets, today announced that the ... been invited to present at the New Frontiers in cancer Drug Development conference which is part of ... entitled "Developing Drug Candidates Directed to cancer Stem Cell Targets: Preclinical and Clinical ...Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
... a patient with progressive breast cancer who experienced a PR (34% shrinkage in ... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the ...Sunesis Reports Financial Results for the Second Quarter 2009
... in women with platinum-resistant ovarian cancer were also presented at the ASCO 2009 Annual ... Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled ... for new treatment options. About Ovarian cancer In the United States, ...Sanofi-aventis Announces Second Quarter 2009 Results
... 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Growth was good ... 34 million, boosted in particular by the prostate cancer indication approved in the second half of 2008. ... , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line ...Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
... profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome ... in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. ... include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and ...NeoGenomics Reports Second Quarter 2009 Results
... capability to perform a portion of their bladder cancer FISH testing in-house while simultaneously ... As a result, revenue from this customer's bladder cancer FISH testing declined by $278,000 in Q2 09 ... to have the opportunity to develop certain other cancer tests over time, and to have Abbott as new 9.6% ...Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
... a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK ... undergoing radiation treatment for head and neck cancer experience some level of oral mucositis. This ... patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation ...Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
... programs highlighted by our bavituximab Phase II cancer program, which is already generating promising ... in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product ...NewLink Genetics Corporation Closes $7.5 Million Financing
... the clinical development of its therapeutic cancer products. This financing involved additional ... one of the leaders in the expanding field of cancer immunotherapy," said Dr. Charles Link, Chairman ... our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our ...Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
... has now received all the remaining six novel cancer drug candidates from Santaris Pharma and Enzon ... associated with schizophrenia. Clin cancer Research In January 2009 Santaris Pharma ... suppressive microRNAs in lung cancer. cancer Research In January 2009 Santaris Pharma ...ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens
... into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen ... platform to develop DPX-0907, a therapeutic cancer vaccine. Within the next six months the company ... licensing agreement significantly advances our cancer immunotherapy capabilities and represents our ...Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
... focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell ... of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. ...USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk
... University Hospital and USC Kenneth Norris, Jr. cancer Hospital at the University of Southern ... University Hospital and USC Kenneth Norris, Jr. cancer Hospital will continue to use the Quantros Safety ... teaching hospital closely aligned with USC Norris cancer Hospital and staffed by the faculty of USC's Keck ...First Catalog Cancer Biochip for Sequence Capture Now Available from febit
... announced today the launch of the first human cancer biochip for HybSelect, febit's highly automated ... Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute. ...Johnson & Johnson Completes Acquisition of Cougar Biotechnology
... with metastatic, castration-resistant prostate cancer who have progressed after docetaxel-based ... with metastatic, castration-resistant prostate cancer who have yet to receive chemotherapy. One in six men will be diagnosed with prostate cancer in his lifetime, and the disease accounts for 10 ...